Home-Based Administration of depo-subQ provera 104™ in the Uniject™ Injection System

This literature review details the key findings on the feasibility and acceptability of home delivery of depo-subQ provera 104™ in the Uniject™ injection system (depo-subQ in Uniject). The review focused on self-injection and looked specifically at subcutaneous depot medroxyprogesterone acetate (DMPA) compared to the intramuscular formulation; considerations for home administration of injectable contraception, particularly in low-resource settings; and identified research needs for home administration, including self-injection, of depo-subQ in Uniject. A six-page briefing summary of this review is also available.

Author(s): Keith BM

Corporate author(s): PATH

Publication date: July 2011

Available materials

English

Home-Based Administration of depo-subQ provera 104™ in the Uniject™ Injection System (literature review)

1,205 KB PDF

Hard copies are not available.

Home-Based Administration of depo-subQ in the Uniject Injection System (briefing summary)

1,559 KB PDF

Hard copies are not available.

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Region: Global

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA